Tatva Chintan Pharma Chem Ltd

Tatva Chintan Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Tatva Chintan Pharma Chem Ltd

₹ 1,209 0.35%
13 Apr 3:40 p.m.
tatvachintan.com BSE: 543321 NSE: TATVA
About

Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]

Key Points

Product Portfolio:
Tatva Chintan has a portfolio of 214 products divided into 4 categories: [1]
a) Pharmaceuticals & Agrochemicals Intermediates and other Specialty Chemicals (PASC):[2][3] PASC is used to produce intermediates, catalysts, and solvents for industries like pharmaceuticals, agrochemicals, and disinfectants. The company specializes in manufacturing Glymes, a solvent essential for API production. It is India's largest Glyme producer and ranks 3rd globally. [4] [5] [6]
b) Structure Directing Agents (SDA):
The company manufactures SDAs, a crucial raw material for producing high-precision zeolites, which find industrial uses as catalysts and adsorbents across automotive, petrochemicals and other industries. It is the 2nd largest manufacturer of SDAs for Zeolites globally and the largest commercial supplier in India.[7] [6]
c) Phase Transfer Catalyst (PTC):
The company is India’s leading producer of PTC. PTCs play a key role in heterogeneous multiphase systems by aiding reactant migration. They are utilized in pharmaceutical APIs, agrochemicals, flavors and fragrances, and environmental control processes.[7][6]
d) Electrolyte Salts & Others:
Electrolyte Salts are used to manufacture supercapacitor batteries. The company is India’s largest producer of electrolyte salts and solutions for supercapacitor batteries. It also manufactures Brominated Flame Retardants, essential in the construction, electronics, and automotive industries. [8]

Website BSE NSE
  • Market Cap ₹ 2,828 Cr.
  • Current Price ₹ 1,209
  • High / Low ₹ 1,610 / 672
  • Stock P/E 90.8
  • Book Value ₹ 313
  • Dividend Yield 0.08 %
  • ROCE 0.26 %
  • ROE 0.05 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 245%

Cons

  • Stock is trading at 3.98 times its book value
  • The company has delivered a poor sales growth of 7.62% over past five years.
  • Company has a low return on equity of 4.03% over last 3 years.
  • Promoter holding has decreased over last 3 years: -7.15%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of BSE Allcap BSE Commodities

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
114 119 106 93 86 94 94 81 84 108 109 116 139
97 104 86 72 74 80 86 76 78 100 94 95 112
Operating Profit 17 15 20 21 12 14 8 5 6 8 15 21 27
OPM % 15% 13% 18% 22% 14% 15% 8% 6% 7% 7% 14% 18% 19%
1 -3 1 1 1 5 1 1 0 1 1 1 2
Interest 2 3 3 3 0 0 0 0 0 0 0 1 0
Depreciation 2 3 6 7 7 6 7 7 7 7 9 9 9
Profit before tax 13 7 12 12 7 12 2 -2 -2 2 7 12 19
Tax % 20% -134% 30% 30% 29% 33% 29% -30% -30% 30% 27% 28% 15%
11 16 8 8 5 8 2 -1 -1 1 5 9 16
EPS in Rs 4.76 7.29 3.72 3.51 1.99 3.53 0.65 -0.47 -0.50 0.47 2.19 3.82 6.83
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
131 203 254 291 428 403 379 366 471
110 170 201 226 322 348 312 340 401
Operating Profit 22 33 53 65 106 55 67 26 71
OPM % 16% 16% 21% 22% 25% 14% 18% 7% 15%
2 1 1 5 11 2 7 3 5
Interest 3 4 4 4 5 9 7 1 2
Depreciation 3 4 5 7 8 10 26 28 34
Profit before tax 18 26 44 59 103 39 42 0 40
Tax % 38% 24% 21% 13% 7% -4% 31% 28%
11 20 35 51 96 40 29 0 31
EPS in Rs 13.74 25.13 43.51 25.57 43.31 18.26 12.55 0.14 13.31
Dividend Payout % 0% 0% 0% 20% 5% 11% 16% 709%
Compounded Sales Growth
10 Years: %
5 Years: 8%
3 Years: -5%
TTM: 34%
Compounded Profit Growth
10 Years: %
5 Years: -60%
3 Years: -84%
TTM: 316%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -10%
1 Year: 73%
Return on Equity
10 Years: %
5 Years: 10%
3 Years: 4%
Last Year: 0%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 8 8 8 20 22 22 23 23 23
Reserves 51 72 106 142 447 483 702 698 710
56 77 91 90 120 170 14 36 83
29 31 40 58 87 80 75 65 90
Total Liabilities 145 187 245 310 676 755 815 823 906
57 67 111 120 160 196 427 529 515
CWIP 10 6 5 10 51 231 77 24 80
Investments 1 1 1 1 1 1 11 1 1
76 114 129 179 464 327 301 269 310
Total Assets 145 187 245 310 676 755 815 823 906

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
25 19 20 24 103 24
-40 -21 -197 -101 -121 -65
10 -5 235 38 31 17
Net Cash Flow -6 -6 58 -40 13 -25
Free Cash Flow -24 -2 -69 -179 -26 -52
CFO/OP 61% 44% 36% 57% 163% 108%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 92 80 73 113 53 82 66 76
Inventory Days 134 98 165 168 299 249 313 228
Days Payable 132 70 88 116 82 52 96 60
Cash Conversion Cycle 94 109 150 166 269 278 282 244
Working Capital Days 16 46 45 73 72 22 154 139
ROCE % 22% 27% 28% 26% 8% 7% 0%

Insights

In beta
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Combined Assembly Lines
Nos

Log in to view insights

Please log in to see hidden values.

Login
Combined Installed Reactor Capacity
KL
Quality Control and QA Employees
Nos
R&D Employees
Nos
Pharma & Agro Intermediates (PASC) Revenue
INR Mn
Phase Transfer Catalyst (PTC) Revenue
INR Mn
Structured Directing Agents (SDA) Revenue
INR Mn
R&D Expenditure (Percentage of Turnover)
%

Shareholding Pattern

Numbers in percentages

4 Recently
Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
79.17% 79.17% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02%
3.54% 3.19% 4.40% 4.21% 3.65% 3.37% 3.33% 3.36% 3.30% 3.26% 3.40% 4.17%
11.71% 11.07% 13.78% 13.06% 12.84% 10.64% 6.83% 6.34% 5.46% 5.11% 3.87% 3.32%
5.59% 6.56% 9.79% 10.72% 11.49% 13.97% 17.81% 18.27% 19.21% 19.60% 20.72% 20.49%
No. of Shareholders 70,03770,79974,62874,51973,73073,91279,62379,00978,39376,79273,33168,657

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls